Effective viral clearance studies remain one of the challenges facing manufacturers of biologics. These studies are an essential part of process validation and are critical to ensure drug safety. This article provides the basics of what you need to know when studying virus reduction of a chromatography step.
Despite such a clear link between AD and the buildup of beta-amyloid plaques, researchers and drug companies have not been successful in developing an effective therapy that targets beta-amyloid. Fortunately, there are several studies targeting beta-amyloid.